Advances Research in Radiopharmaceuticals for Diagnosis and Therapy
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 619
Special Issue Editors
Interests: radiochemistry; radiopharmaceutical; molecular imaging; PET; SPECT
Interests: molecular imaging; radiopharmaceuticals; radiochemistry; theranostics; PET; drug delivery system; oncology; infection
Special Issue Information
Dear Colleagues,
In recent decades, radiopharmaceuticals (RPs) have been developed as state-of-the-art technologies to detect and understand various diseases, ranging from oncology, infectious diseases, neuro-oncology and neurodegenerative diseases. The advances in RPs also expanded the role of target-specific molecular imaging in modern patient care by supporting clinical decision making, monitoring responses to treatment, and improving treatment outcomes. In addition to this, recent developments of therapeutic RPs using At-211 and Ac-225, along with conventional I-131, Re-188 and Lu-177, are leading to the development of nuclear medicine in the field of radionuclide treatment. However, many questions remain unanswered regarding how radionuclides are recognized in the scientific community and clinical practice. This Special Issue aims to introduce recent advances in the development of various RPs in diagnosis and therapy. Original research articles and comprehensive reviews that represent a leap forward in the medical practice of theranostics are welcome. This Special Issue focuses on, but is not limited to, the following topics: novel radiochemistry, automatic production of RPs based on GMP, development of novel diagnostic and therapeutic RPs, production of radioisotope, pharmacokinetics/pharmacodynamics, and other applications of RPs for clinical research.
Prof. Dr. Byung Seok Moon
Prof. Dr. Dong-Yeon Kim
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- molecular imaging
- PET
- theranostics
- SPECT
- radioisotopes
- automatic production
- hybrid imaging
- nanomedicine
- radiochemistry
